Full Text
Cost-Effectiveness Of Once Daily Dolutegravir Versus Twice Daily Raltegravir As First-Line Antiretroviral Therapy In Hiv-Infected Adults In The United States

Abstract

Authors

N. Keeling A. Crumby S. Nunna

Back to Volume 17, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×